Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rosova+ is an investigational oral fixed-dose combination small-molecule candidate from Indication Biosciences in the Statin+ platform for hypercholesterolemia, statin intolerance, and cardiovascular disease. It is described as a rosuvastatin-based combination that pairs rosuvastatin with an undisclosed complementary FDA-approved small molecule. Its intended pharmacology is lipid lowering driven by the established statin mechanism, principally inhibition of **3-hydroxy-3-methylglutaryl-coenzyme A reductase**, with the second component intended to improve tolerability and or therapeutic performance, although the partner molecule and its precise target biology have not been publicly disclosed. The company lists the program as preclinical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rosova+.